State-of the-Art Review : Prevention of Thrombosis in Gynecologic Malignancy

Nordström M. , Lindblad B. , Anderson H. , et al. Deep venous thrombosis and occult malignancy: an epidemiological study. Br Med J 1994;308:891.

Prandoni P. , Lensing Awa , Büller HR , et al. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992;327:1128.

Nordström M. , Lindblad B. , Bergqvist D. , Kjellström T. A prospective study of the incidence of deep vein thrombosis within a defined urban population . J Int Med 1992;232:155.

Monreal M. , Lafoz E. , Casals A. , et al. Occult cancer in patients with deep venous thrombosis. Cancer 1991;67:541.

Aderka D. , Brown A. , Zellikovski A. , Pinkhas J. Idiopathic deep vein thrombosis in an apparently healthy patient as a premonitory sign of occult cancer. Cancer 1986;57:1846.

Constantini V. , Zacharski LR Fibrin and cancer. Thromb Haemost 1993;69:406.

Geczy CL Cellular mechanism for the activation of blood coagulation. Int Rev Cytol 1994;152:49.

Lindahl AK Blood coagulation inhibitors in malignant disease. Norwegian Cancer Society, Oslo, Norway, 1992 .

Contrino J. , Hao G. , Kreutzer DL , Rickles FR In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996;2:209.

Nicolaides AN , Irving D. Clinical factors and the risk of deep venous thrombosis. In: Nicolaides AN , ed. Thromboembolism. Lancaster: MTP Co., Ltd, 1975:193.

Pinsky DJ , Yan SF , Lawson CH , et al. Hypoxia and modification of the endothelium: Implications for regulation of vascular hemostatic properties. Cell Bio 1995;6:283.

Tempelhoff v G-F , Heilmann L. Alterations in the clotting system and hemorrheologie: early signs of thrombophilia in patients with different gynecologic malignancies [Abstract]. Br J Haematol 1994;87(suppl 1);191.

Lowe Gdo. Blood rheology, hemostasis and vascular disease. In: Bloom AL , Forbes CD , Thomas DP , Tuddenham ECD , eds. Haemostasis and Thrombosis. New York: Churchill Livingstone, 1994 .

Miller B. , Heilmann L. Hemorrheological parameters in patients with gynecologic malignancies . Gynecol Oncol 1989;33:177.

Tempelhoff v G-F , Dietrich M. , Niemann F. , et al. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 1997;77:456.

Ogawa S. , Gerlach A. , Esposito C. , et al. Hypoxia modulates the barrier in coagulant function of cultured bovine endothelium. J Clin Invest 1990;85:1090.

Jain RK Transport of molecules across tumor vasculature. Cancer Met Rev 1987;6:559.

Warren BA The vascular morphology of tumors. In: Peterson HJ , ed. Tumor Blood Circulation, Angiogenesis, Vascular Morphology and Blood Flow in Experimental and Human Tumours. Boca Raton: CRC Press, 1979.

Walsh JJ , Bonnar J. , Wright FW A study of pulmonary embolism and deep leg vein thrombosis after major gynecologic surgery using labelled fibrinogen phlebography and lung scanning . J Obstet Gynecol Br 1984 ;81:311.

Adolf J. , Buttermann JG , Weidenbach A. , Gmeinder F. Optimierung der postoperativen Thromboseprophylaxe in der Gyndkologie . Geburtsh u Frauenheilk 1978;38:98.

Ballard RM , Bradley-Watson PJ , Johnstone FD , et al. Low dose of subcutaneous heparin in the prevention of deep vein thrombosis after gynecological surgery. J Obstet Gynecol Br 1973;80:469.

Bonnar J. , Walsh J. Prevention of thrombosis after pelvic surgery by British Dextran 70 . Lancet 1972;II:614.

Turner G. , Brooks J. The efficacy of graduated compression stockings in the prevention of deep vein thrombosis after major gynecologic surgery. Br J Obstet Gynecol 1984 ;91:588.

Clarke-Pearson DL , deLong E. , Synan IS , et al. A controlled trial of two dose low dose heparin regimens for the prevention of postoperative deep vein thrombosis . Obstet Gynecol 1990 ;75:684.

Clarke-Pearson DL , Synan I. , Hinshaw W. , et al. Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. Obstet Gynecol 1984;63:92.

Clarke-Pearson DL , Coleman RE , Synan IS , et al. Venous thromboembolism prophylaxis in gynecologic oncology: a prospective controlled trial of low dose heparin . Am J Obstet Gynecol 1983; 145:606.

Clarke-Pearson DL , Creasman WI , Coleman RE , et al. Perioperative external pneumatic calf compression as thromboembolism prophylaxis in gynecologic oncology: report of a randomized controlled trial: Gynecol Oncol 1984;18:226.

Heilmann L. , Kruck A. , Schindler E. Thromboseprophylaxe in der Gyndkologie: Doppelblindvergleich zwischen niedermolekularen (LMWH) und unfraktionierten (UFH) Heparin. Geburtsh und Frauenheilk 1989;48:803.

Hohl MK , Lüscher KP , Tickey J. , et al. Prevention of postoperative thromboembolism by Dextran 70 or low dose heparin. Obstet Gynecol 1980;55:497.

Kunz S. , Drähne A. , Briel RC Propkylaxe der postoperativen Thromboembolie—Erfahrungen mit Heparin-Dihydergot in der Gynäkologie. In: Pabst HW , Maurer G , eds. Postoperative Thromboembolie-Prophylaxe . Stuttgart: Schattauer, 1977.

McCarthy TG , McQueen J. , Johnstone FD , et al. A comparison of low dose subcutaneous heparin and intravenous dextran 70 in the prophylaxis of deep venous thrombosis after gynecological surgery. J Obstet Gynecol Br 1974;81:486.

Taberner DA , Poller L. , Bursletor RW , Jones JB Oral anticoagulants controlled by the British comparative thromboplastin versus low dose heparin in prophylaxis of deep vein thrombosis. Br Med J 1978;1:272.

Clarke-Pearson DL , Synan IS , Dodge R. , et al. A randomized trial of low dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery . Am J Obstet Gynecol 1993;168:1146.

Heilmann L. , von Tempelhoff GF , Herrle B. , et al. Low dose heparin versus niedermolekulares Heparin zur Thromboseprophylaxe in der operativen gyndkologischen Onkologie . Geburtsh u Frauenheilk 1997;57:1.

Kakkar VV Prevention of venous thromboembolism. In: Bloom AI , Forbes CD , Thomas DP , Tuddenham EGD , eds. Haemostasis and Thrombosis. London : Churchill Livingstone, 1994.

Gallus A. , Cade J. , Ockelford P. , et al. Orgaran (ORG 10172) or Heparin for preventing venous thrombosis after elective surgery for malignant diseases? A double blind randomized comparison . Thromb Haemost 1993;70:562.

Kakkar VV Effectiveness and safety of low molecular weight heparins (LMWH) in the prevention of venous thrombembolism (VTE). Thromb Haemost 1995;74:364.

Borstadt E. , Urdahl K. , Handerland G. , Abildgaard U. Comparison of low molecular weight heparin vs. unfractionated heparin in gynecological surgery. Acta Obstet Gynecol Scand 1988;67:99.

Fareed J. , Callas DJ , Hoppensteadt D. , et al. Recent developments in antithrombotic agents. Exp Opin Invest Drugs 1995;4:389.

Bona RD , Sivjee KY , Hickey AD The efficacy and safety of oral anticoagulance in patients with cancer . Thromb Haemost 1995;74: 1055.

Friend JR , Kakkar VV Deep vein thrombosis in obstetric and gynecological patients. In: Kakkar VV , Jonkar ZJ , eds. Thromboembolism Diagnosis and Treatment . New York: Churchill Livingston , 1972 .

Gore M. , Miller KE , Soong SJ , et al. Vascular plasminogen activator levels and thromboembolic disease in patients with gynecologic malignancy. Am J Obstet Gynecol 1984; 149:830.

Clahsen PC , van de Velde CJH , Julien JP , et al. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European organization for research and treatment of cancer breast cancer cooperative group study. J Clin Oncol 1994;12:1266.

Saphner T. , Tormey DC , Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991 ;9:286.

Weiss RB , Dormey DC , Holland JF Venous thrombosis during multimodal treatment of primary breast carcinoma . Cancer Treat Rep 1981;65:677.

Levine M. , Hirsh J. , Gent M. , et al. Double-blind randomized of very low dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886.

Tempelhoff v G-F , Dietrich M. , Hommel G. , Heilmann L. Blood coagulation during adjuvant epirubicin/cyclophosphamid chemotherapy in patients with primary operable breast cancer. J Clin Oncol 1996 ;14:2560.

Goodnough LT , Saito H. , Manni A. Increased incidence of thromboembolism in stage IV breast cancer patients treated with five drug chemotherapy regimen: a study of 159 patients. Cancer 1984; 54:1264.

Canney PA , Wilkinson PM Pulmonary embolism in patients receiving chemotherapy for advanced ovarian cancer. Europ J Cancer Clin Oncol 1985 ;21:585.

Bick RL , Fekete LF , Wilson WL Adriamycin and fibrinolysis. Thromb Res 1976 ;8:467.

Canobbio L. , Fassio T. , Ardizzoni A. , et al. Hypercoagulable state induced by cytostatic drugs in stage II breast cancer patients. Cancer 1986;58:1032.

Fisher B. , Constantino J. , Redmond C. Randomized clinical trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen-positive tumors . N Engl J Med 1989;320:474.

Pollow K. , Kreienberg R. , Juchem M. , Hoffmann G. Hochdosierte Medroxyprogesteronacetat (MPA)-therapie beim fortgeschrittenen mammakarzinom unter besonderer berucksichtigung der MPAserumspiegel. Tumordiagn u Ther 1995;14:49.

Rutqvist LE , Mattson A. Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1993 ; 85:1398.

Pemberton KD , Melissari E. , Kakkar VV The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coag Fibrinolys 1993;4:935.

Lipton A. , Harvey HA , Hamilton RW Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep 1984;68:887.

McDonald CC , Alexander FE , Whyte BW , et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. Br Med J 1995;311:977.

Hayes DF , van Zyl JA , Hacking A. , et al. Randomized comparison of tamoxifen and two separate doses of toremifen in postmenopausal patients with metastatic breast cancer. J Clin Oncol 1995; 13:2556.

Anker G. , Lonning PE , Ueland PM , et al. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. Int J Cancer 1995;60: 365.

Bastert G. , Michel RI Hochdosierte Gestagentherapie mit medroxyprogesteronacetat (HD-MPA) beim metastasierenden Mammakarzinom. Med Welt 1983;34:378.

Castiglione-Gertsch M. , Pampallona S. , Varini M. , et al. Primary endocrine therapy for advanced breast cancer: To start with tamoxifen or with medroxyprogesteron acetate ? Ann Oncol 1993; 4:735.

Davila E. , Vogel Chl , East D. , et al. Clinical trial of high dose oral medroxyprogesteron acetate in the treatment of metastatic breast cancer and review of the literature . Cancer 1988;61:2161.

Della Cuna Robustelli G. , Pellegrini A. , Ganzina F. Chemotherapy and hormonal treatment of advanced breast cancer. Farmitalia, Milano, 1982.

Merckle E. , Bähr I. , Henke A. , et al. Sequenz und intervalltherapie beim metastasierende mammakarzinom mit tamoxifen und MPA. Tumordiagn u Ther 1994 ;15:104.

Pannuti F. , Martoni A. , Cilenti G. , et al. Adjuvant therapy for operable breast cancer with medroxyprogesteron acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients. Eur J Cancer Clin Oncol 1988;24:423.

Samonis G. , Magioris AN , Bafaloukos D. , Razis DV Prospective randomized study of aminoglutethimide (AG) versus medroxyprogesterone acetate (MPA) versus AG + MPA in generalized breast cancer. Oncology 1994 ;51:411.

Parnes HL , Abrams JS , Tchekmeydyian NS , et al. A phase I/II study of high dose megestrol acetat in the treatment of metastatic breast cancer. Breast Cancer Res Treat 1991;18:171.

Tchekmedyian NS , Tait N. , Abrams J. , Aisner J. High-dose megestrol acetate in the treatment of advanced breast cancer. Semin Oncol 1988 ;15(suppl 1):44.

Anzivino F. , Pollutri E. , Andollina A. , et al. High doses of medroxyprogesteron acetate in oncology: Effects on the main parameters involved in blood clotting. IRCS Med Sc 1997;5:577.

Yamamoto H. , Noguchi S. , Miyauchi K. , et al. Changes in hamatologic parameters during treatment with medroxyprogesterone acetate for breast cancer . Jpn J Cancer Res 1991 ;82:420.

Kakkar VV , Cohen AT , Edmonson RA , et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993;341:259.

Settembrini PG , Olivari N. , Codemo R. , et al. Evaluation of intra-and post-operative tolerability of the LMWH CY 216 in neoplastic patients [Abstract]. Thromb Haemost 1991 ;65:928.

Hommes DW , Bura A. , Mazzolai L. , et al. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. Ann Int Med 1992; 116:279.

Zacharski LR , Henderson WG , Forman WB Bleeding complications from warfarin anticoagulation in patients with malignancy. J Med 1985;16:535.

Prandoni P. Prevention and treatment of deep vein thrombosis in cancer patients. Vessels 1996;2:31.

Bonnar J. Venous thromboembolism and gynecologic surgery. Clin Obstet Gynecol 1985;28:432.

Tyrell DJ , Kilfeather ST , Page CB Therapeutic uses of heparin beyond its traditional role as an anticoagulant . TiPs 1995;16:198.

Ferrara N. Vascular endothelial growth factor. TCM 1993 ;3:244.

Hayes DF Angiogenesis and breast cancer. In: Shapiro CH, Henderson IC, eds. New directions in breast cancer: research and therapeutics. Hematol/Oncol Clin North Am 1994;8:51.

Norrby K. , Ostergaard P. Basic fibroblast growth factor mediated de novo angiogenesis is more effectively suppressed by low molecular weight heparin than by high molecular weight heparin . Int J Microcirc Clin Exp 1996;16:8.

Wellstein A. Growth factor targeted and conventional therapy of breast cancer. Breast Cancer Res Treat 1994;31:141.

Marsh N. Does heparin stimulate fibrinolysis? Br J Haematol 1990;76:163.

Hirsh J. , Siragusa S. , Cosmi B. , Ginsberg JS Low molecular weight heparin (LMWH) in the treatment of patients with an acute venous thrombembolism. Thromb Haemost 1995 ;74:360.

Hull RB , Raskob GE , Pineo GF , et al. Subcutaneous low molecular weight heparin compared with intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992;326:975.

Hull RB , Pineo GF Therapeutic use of low molecular weight heparins: Knowledge to date and their application to therapy. Semin Thromb Hemost 1994;20;339.

Lensing Awa , Prins MH , Davidson BL , Hirsh J. Treatment of deep venous thrombosis with low molecular weight heparins. A metaanalysis. Arch Int Med 1995;155:601.

Prandoni P. , Lensing Awa , Büller HR , et al. Comparison of subcutaneous low moleculare weight heparin with intravenous standard heparin in proximal deep vein thrombosis . Lancet 1992;339: 441.